Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Olaparib Oral Product|DRUG: Olaparib Oral Product in combination with Durvalumab
Sponsor: Duke University
Collaborators: AstraZeneca